Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy

Designing an RNA-interacting molecule that displays high therapeutic efficacy while retaining specificity within a broad concentration range remains a challenging task. Risdiplam is an FDA-approved small molecule for the treatment of spinal muscular atrophy (SMA), the leading genetic cause of infant...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottesen, Eric W, Singh, Natalia N, Luo, Diou, Kaas, Bailey, Gillette, Benjamin J, Seo, Joonbae, Jorgensen, Hannah J, Singh, Ravindra N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Gene regulation, Chromatin and Epigenetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325915/
https://www.ncbi.nlm.nih.gov/pubmed/37026480
http://dx.doi.org/10.1093/nar/gkad259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325915/
https://www.ncbi.nlm.nih.gov/pubmed/37026480
http://dx.doi.org/10.1093/nar/gkad259

Ejemplares similares